 |
oral testosterone |
|---|---|
| Trade Name | |
| Orphan Indication | Constitutional delay of growth and puberty in adolescent boys 14 to 17 years of age |
| USA Market Approval | USA |
| USA Designation Date | 2016-06-02 00:00:00 |
| Sponsor | TesoRx Pharma, LLC;3670 West Temple Avenue, Suite 270;Pomona, California, 91768 |
